Skip to content

Closed-Loop O2 Use During Invasive Mechanical Ventilation Of Pediatric Patients

Closed-Loop O2 Use During Invasive Mechanical Ventilation Of Pediatric Patients (CLOUDIMPP)- a Randomized Cross-over Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05714527
Acronym
CLOUDIMPP
Enrollment
30
Registered
2023-02-06
Start date
2023-01-30
Completion date
2024-08-31
Last updated
2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Failure

Keywords

Acute respiratory failure (ARF), Pediatric acute respiratory distress syndrome (PARDS), Closed-loop, Oxygen, SpO2

Brief summary

During mechanical ventilation (MV) hypoxemic or hyperoxemic events should be carefully monitored and a quick response should be provided by the caregiver at the bedside. Pediatric mechanical ventilation consensus conference (PEMVECC) guidelines suggest to measure SpO2 in all ventilated children and furthermore to measure partial arterial oxygen pressure (PaO2) in moderate-to-severe disease. There were no predefined upper and lower limits for oxygenation in pediatric guidelines, however, Pediatric acute lung injury consensus conference PALICC guidelines proposed SpO2 between 92 - 97% when positive end-expiratory pressure (PEEP) is smaller than 10 cm H2O and SpO2 of 88 - 92% when PEEP is bigger or equal to 10 cm H2O. For healthy lung, PEMVECC proposed the SpO2\>95% when breathing a FiO2 of 21%. As a rule of thumb, the minimum fraction of inspired O2 (FiO2) to reach these targets should be used. A recent Meta-analyze showed that automated FiO2 adjustment provides a significant improvement of time in target saturations, reduces periods of hyperoxia, and severe hypoxia in preterm infants on positive pressure respiratory support. This study aims to compare the closed-loop FiO2 controller with conventional control of FiO2 during mechanical ventilation of pediatric patients

Interventions

Close-loop FiO2 controller software option provides automated adjustment of the ventilator Oxygen setting to maintain the patient's SpO2 in a defined target range. When using the software option, the user defines the SpO2 target range, as well as the SpO2 emergency limits, and the device adjusts the FiO2 setting to keep the patient's SpO2 in the target range.

DEVICEConventional

Conventional FiO2 adjustment by the clinician according to SpO2 values, by using the manual FiO2 knob.

Sponsors

Hamilton Medical AG
CollaboratorINDUSTRY
Dr. Behcet Uz Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No

Inclusion criteria

* Pediatric patients older than 1 month and younger than18 years of age; hospitalized at the PICU with the intention of treatment with IMV at least for the upcoming 5 hours * Requiring FiO2 ≥ 25% to keep SpO2 in the target ranges defined by the clinician * Written informed consent signed and dated by the patient or one relative in case that the patient is unable to consent, after full explanation of the study by the investigator and prior to study participation

Exclusion criteria

* Patient with indication for immediate noninvasive ventilation (NIMV), High flow oxygen therapy (HFOT) * Hemodynamic instability defined as a need of continuous infusion of epinephrine or norepinephrine \> 1 mg/h * Low quality on the SpO2 measurement using finger and ear sensor (quality index below 60% on the SpO2 sensor, which is displayed by a red or orange colour bar) * Severe acidosis (pH ≤ 7.25) * Pregnant woman * Patients deemed at high risk for the need of non-invasive mechanical ventilation within the next 5 hours * Patients deemed at high risk for the need of transportation from PICU to another ward, diagnostic unit or any other hospital * Diseases or conditions which may affect transcutaneous SpO2 measurement such as chronic or acute dyshemoglobinemia: methemoglobinemia, carbon monoxide (CO) poisoning, sickle cell disease * Formalized ethical decision to withhold or withdraw life support * Patient included in another interventional research study under consent * Patient already enrolled in the present study in a previous episode of acute respiratory failure

Design outcomes

Primary

MeasureTime frameDescription
Percentage of time spent in optimal SpO2 range2 hoursThe optimal SpO2 range will be defined according to the SpO2 targets determined by the clinician.

Secondary

MeasureTime frameDescription
Mean FiO22 hoursMean fraction of inspired oxygen
Mean SpO2/FiO22 hoursMean SpO2/FiO2
Number of manual adjustments2 hoursFrequency of manual adjustments of FiO2
Number of alarms2 hoursFrequency of alarms
Percentage of time spent in suboptimal SpO2 range2 hoursSpO2 values outside the optimal range but still within an acceptable limit (2-3 percent above and below the optimal range)
Percentage of time with SpO2 below 88 and 85 percent2 hoursDuration of time with SpO2 \<85 percent and \<88 percent, respectively
Number of events with SpO2 below 88 and 85 percent2 hoursFrequency of SpO2 decreases \<85 percent and \<88 percent, respectively
Percentage of time with FiO2 below 40 percent, 60 percent and 100 percent2 hoursPercentage of time that FiO2 is \<40 percent, 60 percent and 100 percent, respectively
Total oxygen use2 hoursVolume of total oxygen used (in L)
Percentage of time with SpO2 signal available2 hoursTime with SpO2 signal available

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026